In a study of 837 patients with recurrent or chemorefractory ovarian cancer treated with trastuzumab, a response rate of 7% was obtained in 47 patients with ErbB2 overexpressing tumours [75]. This evidence concerns the gene ERBB2 and ovarian carcinoma.